HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pereboeva, L. Articles by Curiel, D.T. Search for Related Content PubMed PubMed Citation Articles by Pereboeva, L. Articles by Curiel, D.T.

Approaches to Utilize Mesenchymal Progenitor Cells as Cellular Vehicles

^a Division of Human Gene Therapy, Departments of Medicine, Pathology, and Surgery, and the Gene Therapy Center, University of Alabama at Birmingham, Birmingham, Alabama, USA;
^b VectorLogics, Inc., Birmingham, Alabama, USA

Key Words. Mesenchymal progenitor cells • Cellular vehicles • Gene delivery • Adenovirus • Thymidine kinase

Larisa Pereboeva, M.D., Ph.D., Division of Human Gene Therapy, Gene Therapy Center, University of Alabama at Birmingham, 901 19th Street South, BMR2-572, Birmingham, Alabama 35294-3300, USA. Telephone: 205-975-8768; Fax: 205-975-2961; e-mail: larisa.pereboeva{at}ccc.uab.edu

Mammalian cells represent a novel vector approach for gene delivery that overcomes major drawbacks of viral and nonviral vectors and couples cell therapy with gene delivery. A variety of cell types have been tested in this regard, confirming that the ideal cellular vector system for ex vivo gene therapy has to comply with stringent criteria and is yet to be found. Several properties of mesenchymal progenitor cells (MPCs), such as easy access and simple isolation and propagation procedures, make these cells attractive candidates as cellular vehicles. In the current work, we evaluated the potential utility of MPCs as cellular vectors with the intent to use them in the cancer therapy context. When conventional adenoviral (Ad) vectors were used for MPC transduction, the highest transduction efficiency of MPCs was 40%. We demonstrated that Ad primary-binding receptors were poorly expressed on MPCs, while the secondary Ad receptors and integrins presented in sufficient amounts. By employing Ad vectors with incorporated integrin-binding motifs (Ad5lucRGD), MPC transduction was augmented tenfold, achieving efficient genetic loading of MPCs with reporter and anticancer genes. MPCs expressing thymidine kinase were able to exert a bystander killing effect on the cancer cell line SKOV3ip1 in vitro. In addition, we found that MPCs were able to support Ad replication, and thus can be used as cell vectors to deliver oncolytic viruses. Our results show that MPCs can foster expression of suicide genes or support replication of adenoviruses as potential anticancer therapeutic payloads. These findings are consistent with the concept that MPCs possess key properties that ensure their employment as cellular vehicles and can be used to deliver either therapeutic genes or viruses to tumor sites.

This article has been cited by other articles:

				R.M. Dwyer, S.M. Potter-Beirne, K.A. Harrington, A.J. Lowery, E. Hennessy, J.M. Murphy, F.P. Barry, T. O'Brien, and M.J. Kerin Monocyte Chemotactic Protein-1 Secreted by Primary Breast Tumors Stimulates Migration of Mesenchymal Stem Cells Clin. Cancer Res., September 1, 2007; 13(17): 5020 - 5027. [Abstract] [Full Text] [PDF]

				H. Xin, M. Kanehira, H. Mizuguchi, T. Hayakawa, T. Kikuchi, T. Nukiwa, and Y. Saijo Targeted Delivery of CX3CL1 to Multiple Lung Tumors by Mesenchymal Stem Cells Stem Cells, July 1, 2007; 25(7): 1618 - 1626. [Abstract] [Full Text] [PDF]

				Q. He, C. Wan, and G. Li Concise Review: Multipotent Mesenchymal Stromal Cells in Blood Stem Cells, January 1, 2007; 25(1): 69 - 77. [Abstract] [Full Text] [PDF]

				A. Van Damme, L. Thorrez, L. Ma, H. Vandenburgh, J. Eyckmans, F. Dell'Accio, C. De Bari, F. Luyten, D. Lillicrap, D. Collen, et al. Efficient Lentiviral Transduction and Improved Engraftment of Human Bone Marrow Mesenchymal Cells Stem Cells, April 1, 2006; 24(4): 896 - 907. [Abstract] [Full Text] [PDF]

				S. Komarova, Y. Kawakami, M. A. Stoff-Khalili, D. T. Curiel, and L. Pereboeva Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol. Cancer Ther., March 1, 2006; 5(3): 755 - 766. [Abstract] [Full Text] [PDF]

				K. Tamama, V. H. Fan, L. G. Griffith, H. C. Blair, and A. Wells Epidermal Growth Factor as a Candidate for Ex Vivo Expansion of Bone Marrow-Derived Mesenchymal Stem Cells Stem Cells, March 1, 2006; 24(3): 686 - 695. [Abstract] [Full Text] [PDF]

				T. Tondreau, N. Meuleman, A. Delforge, M. Dejeneffe, R. Leroy, M. Massy, C. Mortier, D. Bron, and L. Lagneaux Mesenchymal Stem Cells Derived from CD133-Positive Cells in Mobilized Peripheral Blood and Cord Blood: Proliferation, Oct4 Expression, and Plasticity Stem Cells, September 1, 2005; 23(8): 1105 - 1112. [Abstract] [Full Text] [PDF]

				J. Chan, K. O'Donoghue, J. de la Fuente, I. A. Roberts, S. Kumar, J. E. Morgan, and N. M. Fisk Human Fetal Mesenchymal Stem Cells as Vehicles for Gene Delivery Stem Cells, January 1, 2005; 23(1): 93 - 102. [Abstract] [Full Text] [PDF]